Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia

@article{Miles2012RiskFA,
  title={Risk factors and treatment of childhood and adolescent Burkitt lymphoma/leukaemia},
  author={Rodney R. Miles and Staci D Arnold and Mitchell S. Cairo},
  journal={British Journal of Haematology},
  year={2012},
  volume={156}
}
Burkitt lymphoma/leukaemia is the most common (40%) form of non‐Hodgkin lymphoma that occurs in children and adolescents. The prognosis of advanced (disseminated) Burkitt lymphoma/leukaemia in children and adolescents three decades ago had a 5‐year event‐free survival (EFS) of <40%, and required combination chemotherapy and radiation therapy over a 1–2 year period. Currently, the prognosis for the same advanced stage has a 5‐year EFS of 85–90% with <6 months of chemotherapy only. Radiation… 
Advances in the diagnosis and treatment of childhood and adolescent B-cell non-Hodgkin lymphoma.
TLDR
The role of hematopoietic stem cell transplantation in children, adolescents, and young adults with relapsed/refractory disease is currently being defined, and novel humoral and cellular immunotherapies, as well as agents targeting specific molecular pathways that drive lymphomagenesis, are exciting developments that are being evaluated in clinical trials.
Silent presentation of multiple metastasis Burkitt lymphoma in a child
TLDR
The case of a 6-year-old boy diagnosed with BL, who presented multiple contrasting elements of the disease: silent symptomatology, without involvement of the bone marrow at first, but with multiorgan infiltration and a fast evolution, despite starting the treatment shortly after the symptoms appeared.
Mature B-Cell Lymphoma and Leukemia in Children and Adolescents—Review of Standard Chemotherapy Regimen and Perspectives
TLDR
The definitive role of rituximab in the treatment of children and adolescents with mature B-NHL needs to be evaluated in prospective controlled clinical trials.
Five decades of low intensity and low survival: adapting intensified regimens to cure pediatric Burkitt lymphoma in Africa.
TLDR
There is a critical need to safely adapt contemporary treatment regimens to optimize curative outcomes amid the resource limitations in regions where BL is endemic, and to identify potential strategies to improve the therapeutic approach for children suffering from BL in sub-Saharan Africa.
Childhood and Adolescence Non-Hodgkin Lymphomas in Low- and Middle-Income Countries
TLDR
More precise determinations of the true epidemiology of pediatric NHL in LMIC are needed, as well as adapted treatment protocols that can be safely and effectively delivered across the heterogeneous circumstances worldwide.
Therapy of Advanced-stage Mature B-cell Lymphoma and Leukemia in Children and Adolescents With Rituximab and Reduced Intensity Induction Chemotherapy (B-NHL 2004M Protocol): The Results of a Multicenter Study
TLDR
Combined therapy with rituximab and intensive ChT with a reduced MTX dose of 1 g/m2 in the 2 induction courses was feasible and produced high cure rates in patients with pediatric advanced-stage mature B-NHL.
Outcome of Early Stage Pediatric Non-Lymphoblastic Non-Hodgkin Lymphoma
TLDR
This largest data of limited stage pediatric non-lymphoblastic NHL from south Asia highlights that good outcomes may be achieved with less intense short course therapy without hospitalization, and that adolescent age is the only poor prognostic factor for outcome.
Adolescent and young adult non‐Hodgkin lymphoma
TLDR
The unique clinical and biological characteristics of NHL occurring in the AYA population are reviewed with a focus on how to achieve similar curative outcomes in AYA that have been established in younger cohorts.
Rituximab in the treatment of childhood mature B‐cell lymphoma: “Where do we go from here”
  • M. Cairo
  • Medicine, Biology
    British journal of haematology
  • 2019
TLDR
Rituximab, a type I anti-CD20 monoclonal antibody, has been successfully demonstrated to significantly induce B-cell apoptosis and facilitate antibodydependent cellular cytot toxicity and complement-dependent cytotoxicity, and has been demonstrated to be safe to combine with several chemotherapy backbones and significantly increase long term EFS in adults with DLBCL and BL.
A step towards the cure of Burkitt's lymphoma in developing countries
  • C. Klumb
  • Medicine
    Revista brasileira de hematologia e hemoterapia
  • 2012
TLDR
A retrospective study of 50 cases of sporadic Burkitt's lymphoma in children and adolescents who were treated with chemotherapy regimens containing intermediate methotrexate doses and provides important information on the approach to BL care in Brazil.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 62 REFERENCES
Chromosome Abnormalities May Correlate With Prognosis in Burkitt/Burkitt-Like Lymphomas of Children and Adolescents: A Report From Children's Cancer Group Study CCG-E08
TLDR
Chromosome abnormalities that involved 13q32 and partial duplication of 1q were associated with poor prognosis and Burkitt-like lymphomas were not associated with CMYC translocations.
Adolescent non‐Hodgkin lymphoma and Hodgkin lymphoma: state of the science
TLDR
This review details the complexities associated with the diagnosis and treatment of adolescent lymphoma and updates the state of the science, with particular emphasis on epidemiology, diagnosis, and proper management of HL and the various subtypes of NHL.
Results of a randomized international study of high-risk central nervous system B non-Hodgkin lymphoma and B acute lymphoblastic leukemia in children and adolescents.
TLDR
Patients with either combined BM/CNS disease at diagnosis or poor response to cyclophosphamide, Oncovin [vincristine], prednisone (COP) reduction therapy had a significantly inferior EFS and S (P < .001).
Improved survival rate in children with stage III and IV B cell non-Hodgkin's lymphoma and leukemia using multi-agent chemotherapy: results of a study of 114 children from the French Pediatric Oncology Society.
  • C. Patte, T. Philip, F. Demeocq
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1986
TLDR
It was shown that CNS prophylaxis and local control of the primary tumor can be achieved by intensive chemotherapy alone, without radiotherapy or debulking surgery, and that B cell non-Hodgkin's lymphoma who have not relapsed 1 year after diagnosis and treatment are generally cured.
Comparison of long-term outcome of children and adolescents with disseminated non-lymphoblastic non-Hodgkin lymphoma treated with COMP or daunomycin-COMP: A report from the Children's Cancer Group.
TLDR
Addition of daunomycin to standard COMP therapy did not improve outcome in pediatric disseminated NLB NHL, and patients with LC disease had a significantly reduced long-term EFS, but were retrieved at a higher rate than patients with SNCC disease, resulting in equivalent long- term survival.
Minimal disease assessment in the treatment of children and adolescents with intermediate‐risk (Stage III/IV) B‐cell non‐Hodgkin lymphoma: a children’s oncology group report
TLDR
The study demonstrated molecular‐disseminated disease in which IgIGHV primer pools could be used to assess MD and supports future investigations to assess the validity and significance of MD screening in a larger cohort of patients with intermediate‐risk mature B‐NHL.
Long-term follow-up of patients treated with COMP or LSA2L2 therapy for childhood non-Hodgkin's lymphoma: a report of CCG-551 from the Childrens Cancer Group.
  • J. Anderson, R. Jenkin, A. Meadows
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1993
TLDR
Treatment success can be expected in 84% of pediatric patients with localized non-Hodgkin's lymphoma and 50% of those with undifferentiated or large-cell disease, and late adverse events are rare.
Phase II window study on rituximab in newly diagnosed pediatric mature B-cell non-Hodgkin's lymphoma and Burkitt leukemia.
TLDR
Rituximab is active as a single-agent in pediatric B-NHL even though the RR was lower than requested in the phase II plan.
The Société Française d'Oncologie Pédiatrique LMB89 protocol: highly effective multiagent chemotherapy tailored to the tumor burden and initial response in 561 unselected children with B-cell lymphomas and L3 leukemia.
TLDR
Multivariate analysis of prognostic factors showed that a lactate dehydrogenase level more than 2-fold the normal value, no response after COP, and age of at least 15 years were associated with a lower EFS in group B, while CNS involvement was the only prognostic factor in group C.
Advanced stage, increased lactate dehydrogenase, and primary site, but not adolescent age (≥ 15 years), are associated with an increased risk of treatment failure in children and adolescents with mature B-cell non-Hodgkin's lymphoma: results of the FAB LMB 96 study.
  • M. Cairo, R. Sposto, C. Patte
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2012
TLDR
LDH level at diagnosis, mediastinal disease, and combined BM-positive/CNS-positive involvement are independent risk factors in children with mature B-cell NHL.
...
1
2
3
4
5
...